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GlutathionePhosphate-activated mitochondrial glutaminase (GLS2) is suggested to be linked with elevated glutamine me-
tabolism. It plays an important role in catalyzing the hydrolysis of glutamine to glutamate. The present study
was to investigate the potent effect of GLS2 on radioresistance of cervical carcinoma. GLS2 was examined in
144 cases of human cervical cancer specimens (58 radioresistant specimens, 86 radiosensitive specimens) and
15 adjacent normal cervical specimens with immunohistochemistry. HeLa cells were treated with a cumulative
dose of 50 Gy X-rays, over 6 months, yielding the resistant sub-line HeLaR. The expressions of GLS2 were mea-
sured by Western blot. Radioresistance was tested by colony survival assay. Apoptosis was determined by ﬂow
cytometry. The levels of glutathione (GSH), reactive oxygen species (ROS), NAD+/NADH ratio and NADP+/
NADPH ratio were detected by quantization assay kit. Xenografts were used to conﬁrm the effect of GLS2 on
radioresistance in vivo. The expressions of GLS2were signiﬁcantly enhanced in tumor tissues of radioresistant pa-
tients compared with that in radiosensitive patients. In vitro, the radioresistant cell line HeLaR exhibited signiﬁ-
cantly increased GLS2 levels than its parental cell line HeLa. GLS2 silenced radioresistant cell HeLaR shows
substantially enhanced radiosensitivity with lower colony survival and higher apoptosis in response to radiation.
In vivo, xenografts with GLS2 silenced HeLaR were more sensitive to radiation. At the molecular level, knock-
down of GLS2 increased the intracellular ROS levels of HeLaR exposed to irradiation by decreasing the produc-
tions of antioxidant GSH, NADH and NADPH. GLS2 may have an important role in radioresistance in cervical
cancer patients.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cervical cancer is one of the most common malignancies among
women worldwide with a high incidence and mortality, especially in
developing countries [1]. In 2008, approximately 530,000 new cases
were diagnosed, with more than 274,000 women dying of the disease
[2]. Radiation therapy is the most broadly used treatment modality in
patients with cervical cancers particularly at an advanced stage or that
cannot be cured surgically [3]. However, despite progress in radiation
technology, local recurrence still occurs in a large proportion of patients
following radiotherapy because of radioresistance. Based on clinicalRadiation Oncology Center and
ilitary Medical University, 30
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ights reserved.evidence, enhanced DNA repair mechanisms [4], hypoxia [5], intrinsic
radioresistance [6] and cellular glutathione [7] are contributing factors
to this resistance. In addition, a growing body of evidence supports
the idea that glutamine metabolism may involve in protecting tumor
cells from lethal ionizing radiation (IR), which have been recognized
as another potential mechanism of resistance to radiotherapy [8,9].
Therefore, we hypothesize that radioresistance is due also, in part, to
altered expression of glutaminase, and we found phosphate-activated
mitochondrial glutaminase (GLS2), the key enzyme in conversion of
glutamine to glutamate and is overexpressed in radioresistant tumor
tissues compared with radiosensitive tumor tissues after radiotherapy
in cervical cancer patients. Thus, to investigate whether glutaminase
could be a regulator of radioresistance and its underlying mechanisms
may lead to advances in the radiotherapy of human cervical cancers.
Glutamine (Gln) is one of the essential nutrients for cancer cells and
is the most abundant free amino acid in humans. Glutaminase (GA) is
the major enzyme that catalyzes the hydrolysis of glutamine to gluta-
mate, which is in turn converted to alpha-ketoglutarate for further
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at least two genes that encode distinct isozymes of GA. GLS1 that
encodes the “kidney-type” isozyme (KGA) is abundantly expressed in
kidney, brain, intestine, immune system cells and in many transformed
cells, with the exception of postnatal liver [11]. GLS2 encodes the “liver-
type” isozyme (LGA) and was originally thought to be present only in
adult liver tissue [12]. Recently, emerging evidences documenting the
presence of GLS2 in brain, pancreas and breast cancer cells have
appeared [13]. Our research group has found that the expression of
GLS2 also occurs in human cervical cancer.
Mitochondrial GA is truly a key metabolic enzyme, hydrolyzing
amino acid Gln that boosts the ability of cells to grow and proliferate.
However, GA's inﬂuence in cell biology and cancer extends far beyond
its use as a major hydrolase in glutamine metabolism [14]. A number
of recent reports have highlighted these “non-metabolic” functions of
GA in regulating tumor cell survival, proliferation [15], metastasis [16],
signal transduction [17], and autophagy [18]. However, the role of GA
in radioresistance has not previously been investigated. On the basis
of the result that GLS2 is overexpressed in radioresistant cervical cancer
tissues, we hypothesized that GLS2 may act as a pivotal factor in induc-
ing radioresistance in cervical cancer. The aim of this study was to eval-
uate the hypothesis that GLS2 may cause radioresistance in cervical
cancer. Thus, long-term X-ray irradiation of HeLa cells was used to gen-
erate the radioresistant cell sub-lines, HeLaR, and we found that GLS2
overexpression is required for sustaining radioresistance of HeLaR.
Additionally we unveiled that silencing GLS2 expression caused down-
regulation of cellular antioxidant glutathione, NADH and NADPH levels,
and then, decreasing depletion of reactive oxygen species (ROS) and
enhancing radiosensitivity of cervical cancer. Our ﬁnding for the ﬁrst
time links GLS2 to radioresistance-associated properties of cervical
carcinomas.
2. Methods and materials
2.1. Ethics statement
Experiments using the animals were conducted with the approval of
theAnimal Care andUseCommittee of ThirdMilitaryMedical University
(Approval ID: SCXK (Military) 2007015), according to the State Science
and Technology Commission Regulations for the Administration of
Affairs Concerning Experimental Animals (1988, China).
The clinical investigation was complied with the ethical standards
laid down in the 1964 Declaration of Helsinki. The protocol of immuno-
histochemistry for patient tissueswas approved by the Ethic Committee
of the ﬁrst Afﬁliated Hospital (Southwest Hospital), Third Military
Medical University (Permit Number: 2012[13]), and all patients or
family members involved have provided written informed consent.
2.2. Patients and specimens
Patientswith locally advanced stage IIB-IVA cervical cancer,whohad
undergone radiotherapy in the Radiation Oncology Center at Southwest
Hospital, Third Military Medical University between 2000 and 2008,
were identiﬁed. The clinical stages of cervical cancer were deﬁned
according to International Federation of Gynecology and Obstetrics
(FIGO). Patients' clinical informationwas collected and stored in a data-
base. Fifty-eight of specimens were selected from patients with local
recurrence or radiation failure after primary radiation therapy, and con-
stituted the radioresistant group. Eighty-six age-matched control spec-
imens were selected from patients who had no local recurrence for at
least 3 years after radiation therapy, which constituted the radiosensi-
tive group. Adjacent normal specimens were collected from 15 cervical
cancer patients who underwent surgery in Southwest Hospital. The
histomorphology of all specimens had been conﬁrmed by the
Department of Pathology, Southwest Hospital.2.3. Cell lines and irradiation
All human cancer cell lines were obtained from the ATCC (Manassas,
VA,USA) and cultured inRPMI 1640medium(GIBCO)orDulbecco'smod-
iﬁed Eagle's medium (GIBCO) supplemented with 10% newborn calf
serum (GIBCO), penicillin (100 U/ml), and streptomycin (0.1 mg/ml)
(Beyotime Institute of Biotechnology, China). Cells were incubated in
5% CO2 at 37 °C and passaged 2–3 times weekly. For X-ray treatment,
cells were cultured in 75 cm2 culture ﬂasks until they reached approx-
imately 75% conﬂuence and then irradiated at 200 cGy/min, at room
temperature, with a high energy linear accelerator (Varian, USA) oper-
ating at 6 MV. Immediately after irradiation, the culture medium was
renewed and then the cells were returned to the incubator. When
HeLa cells incubated to approximately 90% conﬂuence, they were
trypsinized, counted and passaged into new culture ﬂasks. The cells
were treatedwith 2 Gy againwhen they reached about 75% conﬂuence.
X-ray resistant sub-line (HeLaR)was generated by continuous sublethal
irradiation for 6 months with a 2Gy radiation repeated 25 times to
the total dose of 50 Gy. The parental cell line (HeLa) was trypsinized,
counted and passaged under the same conditionswithout ionizing irra-
diation. To control for acute effects of IR, the radioresistant sub-linewas
cultured for over 1–2 months after the last irradiation before being used
in the analyses.
2.4. Construction and preparation of lentivirus for RNAi of GLS2
shRNA-GLS2 (GTGGTCAAACTGCTTCAAGAT) was designed against
GLS2 (accession number: NM_013267) and synthesized as follows:
Forward: 5′- ccggGTGGTCAAACTGCTTCAAGATctcgagATCTTGAAGCAG
TTTGACCACttttttg-3′, and Reverse: 5′- aattcaaaaaaGTGGTCAAACTGC
TTCAAGATctcgagATCTTGAAGCAGTTTGACCAC-3′. These oligos were
annealed and inserted downstream of the U6 promoter on the
lentiviral vector pGCL-GFP (Neuron Biotech). A control vector contain-
ing non-silencing sequence (5′-TTCTCCGAACGTGTCACGT-3′) was sup-
plied by Neuron Biotech Co., Ltd. (Shanghai, China).
Lentiviruses were generated by triple transfection of 80% conﬂuent
HEK293T cells with pGCL-GFP-shGLS2 plasmid, together with pHelper
1.0 and pHelper 2.0 helper plasmids (Neuron Biotech) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Lentivirus was harvested at 48 h and 72 h post transfection, centri-
fuged to remove cell debris, and thenﬁltered through a 0.45 μmcellulose
acetate ﬁlter followed by ultracentrifugation. For lentivirus infection,
HeLaR cells were grown to 70–80% conﬂuence and infected with pGCL-
GFP-shGLS2 lentivirus or control lentivirus, separately, at MOI of 50
(HeLaR). To determine the infection efﬁciency, cells expressing GFP pro-
tein were imaged using laser confocal scanning microscopy (Leica TSC-
SP5, Germany) 4 days after infection. The GFP positive cells were puri-
ﬁed with a FACSCalibur ﬂow cytometer (BD Biosciences).
2.5. Tissue microarrays and immunohistochemistry (IHC)
All slides were prepared from stored pretreatment parafﬁn-
embedded tissue blocks from the cervical cancer patients who
underwent surgery in Southwest Hospital. Brieﬂy, 86 radiosensitive
cervical cancer specimens were made into tissue microarrays using the
tissuearrayerTMA-1(Beecher Instruments, WA, USA) as described previ-
ously [19]. Fifty-eight radioresistant specimens and 15 adjacent normal
cervical specimens were reprocessed into formalin-ﬁxed parafﬁn-
embedded tissue blocks again, and then cut into 4 μm-thickness sections.
The tissue microarrays and tumor sections were routinely dewaxed in
xylene, rinsed in graded ethanol, and ﬁnally rehydrated in double-
distilled water. Endogenous peroxidase activity was blocked by incuba-
tion in 3% hydrogen peroxide methanol for 15 min. Antigen retrieval
was accomplished by heating the slides in 1 mM EDTA solution
(pH8.0). After washing in phosphate-buffered saline and exposure to
10% normal goat serum for 10 min to reduce nonspeciﬁc binding, the
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anti-human GLS2 polyclonal antibody (Epitomics, Burlingame, CA). The
tissue microarrays and sections were stained using the SP method
according to the kit instructions. The instantaneous SP supersensitive
kit (SP-9001) was provided by Beijing Zhongshan Jinqiao biotechnology
Co., Ltd.
2.6. Criteria for assessing immunohistochemical results
For each slide, ﬁve random ﬁelds were selected for scoring and a
mean score of each slide was calculated in ﬁnal analysis. Positive stain-
ing was accessed using a ﬁve scoring system: 0 (no positive cells), 1
(b10% positive cells), 2 (10%–40% positive cells), 3 (40%–70% positive
cells), and 4 (N70% positive cells). To achieve accuracy, the intensity of
positive staining was also used in a four scoring system: 0 (negative
staining), 1 (weak staining exhibited as light yellow), 2 (moderate stain-
ing exhibited as yellow brown), and 3 (strong staining exhibited as
brown). Protein expression index = (intensity score) × (positive
score). Slides were examined and scored independently by two histopa-
thologists blinded to other pathological information.
2.7. Western blotting analysis
Cell extracts were prepared and Western blotting was performed
according to the instruction of RIPA buffer (Biotek Corporation, Beijing,
China). Cell lysates were collected by centrifugation at 12,000 rpm for
15 min at 4 °C, and then transferred to cleanmicrocentrifuge tubes. Pro-
tein concentration was determined with Bradford reagent (Bio-Rad),
and equal amounts of proteins (50 μg) were run on a 10% SDS–PAGE
gel and blotted onto polyvinylidene ﬂuoride membranes. After blocking
for 2 h at room temperaturewith 5% non-fat-drymilk, membraneswere
incubated with anti-GLS2 rabbit polyclonal antibody (Epitomics; 1:500)
and anti-actin antibodies (Santa Cruz Biotechnology) at 4 °C overnight,
respectively. The secondary antibody was HRP-conjugated anti-IgG
(Boster Biotechnology,Wuhan, China).Membraneswere then incubated
with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce,
Rockford, IL, USA) for 1 min and imaged using a Gel Doc XR system
(Bio-Rad).
2.8. Clonogenic assay for radiosensitivity
The cells were seeded into 24-well culture dishes in triplicates (1000
cells to each well). Cells were allowed to form colonies during 1 week,
and then cells were treated with 0, 2, 4, 6, 8, and 10 Gy of X-ray radia-
tion. After 2 weeks, clones were ﬁxed with methanol and stained with
a 1% crystal violet (Beyotime Institute of Biotechnology, China) for
10 min. Stained clones that had more than 50 cells were counted and
cloning efﬁciency calculated as: cloning efﬁciency = (clone number/
total cell number)*100%. The cell survival fraction (SF)was determined.
A cell survival curvewas drafted usingGraphPad Prism5.0 software and
the single-hit multi-target model SF = 1- (1-e−D/D0)N, where SF is the
survival fraction; D, the radiation dose; D0, the mean death dose; and
N, the extrapolated number. The triplicate experiments were done
independently.
2.9. Flow cytometry analysis for apoptosis and cell cycle
All cells were treated with 6 Gy of X-ray radiation. At 48 h post-
irradiation, the cells were harvested, washed twice with PBS and then
stained with Annexin V-APC (Becton Dickinson, San Jose, CA) according
to the manufacturer's protocol. Cell apoptosis analysis was carried out
by ﬂow cytometry (Becton Dickinson FACSCalibur).
For cell cycle analysis, HeLa andHeLaR cellswere treatedwith 6 Gyof
X-ray radiation. At 24 h post-irradiation, the cells were harvested, ﬁxed
with 70% ethanol, and then stored at 4 °C for 24 h. Cell cycle analysiswas carried out by ﬂow cytometry (Becton Dickinson FACSCalibur) at
488 nm.
2.10. Measurement of levels of ROS
Flow cytometry and confocal ﬂuorescence imaging of dihydro-
ethidium (DHE)-ﬂuorescence were used tomeasure cellular ROS levels.
Dihydroethidiumwas oxidized by superoxide to a novel product which
binds to DNA enhancing intracellular ﬂuorescence. About 3 × 105 cells
were harvested, washed with serum-free RPMI culture medium and
incubated with 5 μM DHE (Beyotime Institute of Biotechnology,
China) at 37 °C for 30 min. Then the cells were harvested, washed and
resuspended in serum-free RPMI culture medium. DHE-ﬂuorescence
was analyzed by ﬂow cytometry (excitation wavelength 325 nm, and
emission wavelength 610 nm). Mean ﬂuorescence intensity (MFI) was
calculated after correction for autoﬂuorescence and fold change calcu-
lated relative to unirradiated control.
For confocal microscopy, cells were suspended in serum-free RPMI
culture medium containing 5 μM DHE, and incubated at 37 °C for
30 min. Cellswere slightlywashedwith PBS and imagingwas conducted
by a laser confocal scanning microscopy (Leica TSC-SP5, Germany).
2.11. Measurement of levels of glutathione and NADP+/NADPH ratio
The total glutathione (GSH) and oxidative glutathione (GSSG) were
determined by colorimetric microplate assay kits (Beyotime Institute of
Biotechnology, China). After treatment, about 1 × 107 cells were col-
lected and centrifuged at 10,000 ×g for 10 min at 4 °C. The cells were
resuspended in 20 μl cell medium. Ten microliters of cells was mixed
with 30 μl 5% metaphosphoric acid, then frozen and thawed twice
using liquid nitrogen and 37 °C water. The samples were centrifuged
and the supernatant was used for GSH and GSSG assays. The total GSH
level was measured by the DTNB-GSSG recycling assay [20]. The GSSG
level was quantiﬁed by the same method as for total GSH after the su-
pernatant was treated with 1 mol/L 2-vinylpyridine solution to remove
the reduced GSH. The amount of reduced GSH was obtained by
subtracting the amount of GSSG from that of total GSH.
TheNADP+/NADPH ratiowas determined byNADP+/NADPH quan-
titation colorimetric kit (Biovision, USA). All cells were washed with
PBS, scraped, and collected. After centrifugation, 106 cells in each
group were resuspended in the NADP+/NADPH extraction buffer in-
cluded in the NADP+/NADPH quantiﬁcation kit. The NADP+/NADPH
ratio was determined following the manufacturer's protocol.
2.12. Measurement of intracellular pyridine nucleotides concentration
NADH and NAD+ levels were measured by using the EnzyChrom™
NAD+/NADH Assay Kit (BioAssay Systems, Hayward, CA) according to
manufacturer's instructions. This assay is based on a lactate dehydroge-
nase cycling reaction, in which the formed NADH reduces a formazan
(MTT) reagent. Exponentially grown cells (about 1 × 107 total cells)
were harvested and washed three times with cold PBS. The cells were
then homogenized in a 1.5 ml eppendorf tube with either 100 μl NAD
extraction buffer for NAD determination or 100 μl NADH extraction
buffer for NADH determination. Heated extracts at 60 °C for 5 min
and then added 20 μl Assay Buffer and 100 μl of the opposite extraction
buffer to neutralize the extracts. Brieﬂy vortexed and spined the sam-
ples down at 14,000 rpm for 5 min. Use supernatant for NADH and
NAD+ assays. NADH andNAD+ levelsweremeasured by themicroplate
reader and detected at 565 nm optical density.
2.13. In vivo tumor models
Female athymic BALB/c nude mice 4–6 weeks old were purchased
from the Institute of Experimental Animal of Third Military Medical
University (Chongqing, China). Mice were maintained under speciﬁc
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HeLa cells, HeLaR cells, control cells or GLS2 silenced HeLaR cells
(1 × 106 cells in 100 μl PBS/mouse) at the right hind limb. Irradiation
treatment started once the xenografts were 0.6–0.8 cm in diameter.
Mice were immobilized in a customized harness that exposed the
right hind leg while shielding the remainder of the body behind a
block of 3.5 cm thick lead. Lead shielded mice received 15 Gy of X-ray
radiation by a 6MV-X linear accelerator (Varian, 23-EX) to the exposed
tumor, divided into 5 fractions on days 14, 18, 22, 26, and 30. To obtain
tumor growth curves, three orthogonal tumor diameters were mea-
sured at 3 day intervals with a vernier caliper, and the mean values
were calculated. The animals were sacriﬁced (n = 5 per group) at day
34, then the xenografts were excised and weighed. Tumor volume
was determined based on the following formula: volume = 0.52 ab2,
where a = long diameter and b = short diameter.
2.14. Statistical analysis
The data collected were analyzed using SPSS 13.0 software (SPSS,
Chicago, IL, USA). Data points were expressed as mean ± SE of three in-
dependent experiments. Statistical signiﬁcances were determined by
using Student's t-test,Mann–WhitneyU test or one-way ANOVA. All sta-
tistical tests were two-sided. Differences were considered statistically
signiﬁcant when p-values were less than 0.05.
3. Results
3.1. GLS2 expressions are increased in cervical cancer tissues of
radioresistant patients after radiotherapy
To investigate whether the expressions of GLS2 of cervical cancers
are different in patientswith varying radiosensitivity, we used immuno-
histochemical staining to examine the expressions of GLS2 in the 58
cases of radioresistant tumor tissues, 86 cases of radiosensitive tumor
tissues and 15 cases of adjacent normal tissues. The positive expressionsFig. 1. Expressions of endogenous GLS2 in human cervical cancer tissues of radioresistant pati
normal cervical tissues (A), cervical cancer tissues of radiosensitive patients (B) and radioresista
normal cervical tissues (D), cervical cancer tissues of radiosensitive patients (E) and radioresisof GLS2 in tumor tissues of radioresistant patient were much higher
than those of radiosensitive patients (Fig. 1 B, C, E and F), but no positive
staining had been seen in the adjacent normal cervical tissues (Fig. 1 A,
D). The patient characteristics were described in Table 1. We found that
the expressions of GLS2 were not correlated to the patient's age, tumor
stage, tumor cell type and tumor size (p N 0.05) (Table 1). The results of
immunohistochemical expressions of GLS2 in cervical cancer tissues
(58 radioresistant and 86 radiosensitive) were summarized in Table 1.
The levels of GLS2 staining were highly correlated with radiosensitivity
of cervical cancer (p b 0.05) (Table 2).3.2. Establishment of radioresistant HeLaR subclone cell line
We established radioresistant cell line (HeLaR) by continuously
treating HeLa cells with sublethal irradiation for 6 months. To verify
the radioresistant phenotypes of HeLaR, HeLaR and control HeLa cells
were irradiatedwith a range of radiation doses (2–10 Gy) andwere ex-
amined by clonogenic survival assay. Clonogenic survival assay is
regarded as the gold standard for radiosensitivity [21]. As shown in
Fig. 2A, HeLaR showed decreased radiosensitivity compared with con-
trol HeLa. Radiation-survival curves were derived from clonogenic sur-
vival assays of the two cell lines after different doses of X-rays (Fig. 2B).
Additionally, HeLaR andHeLawere subjected to 6 Gy radiation to exam-
ine the effect on apoptosis. As shown in Fig. 2C, D, the apoptosis rate of
HeLa cells was much higher than that of the radioresisitant HeLaR sub-
line cells. Furthermore, the cell cycle distribution of HeLaR and HeLa
cells after X-ray irradiation was determined by ﬂow cytometry. As
shown in Fig. 2E, F, 24 h after 6 Gy irradiation, HeLaR cells were found
detained more cells in S phase with less cells in G2-M phase compared
with HeLa cells, suggesting that the regulation of cell cycle induced by
ionizing radiation is altered in the radioresistant HeLaR, which is also
consistent with the typical radioresistant phenotype. All these results
indicate that the sub-lineHeLaR ismore radioresistant than the parental
HeLa cell line.ents and radiosensitive patients. The immunohistochemistry staining of GLS2 in adjacent
nt patients (C). The bottompanel shows highermagniﬁcation of GLS2 staining in adjacent
tant patients (F). Scale bar = 50 μm.
Table 1
Patient characteristics.
Characteristics Radiation-resistant
(n = 86)
Radiation-sensitive
(n = 58)
p-Value
Age(mean) 60 61 N0.05
b50 33 21
≥50 53 37
Stage N0.05
IIB 17 14
IIIA 31 11
IIIB 29 23
IVA 9 10
Cell type N0.05
Squamous carcinoma 68 47
Adenocarcinoma 18 11
Size(cm) N0.05
b4.0 cm 55 39
≥4.0 cm 31 19
Primary treatment
RT 81 55
CCRT 5a 3b
RT: radiation therapy, CCRT: concurrent chemoradiation therapy.
a Cisplatin + 5FU.
b Cisplatin + 5FU (n = 2) and weekly Cisplatin (n = 1).
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in vitro
We measured the GLS2 levels in different cancer cell lines HepG2,
HT29, A549, CE109,MCF-7, SGC7901,HeLa and SW620, and had veriﬁed
that GLS2 were only expressed in MCF-7 and HeLa cells (Fig. 3A). We
further detected the expressions of GLS2 in radioresistant HeLaR cells
together with their wild type cells. We found that the expressions of
GLS2 were much higher in HeLaR than that in HeLa (Fig. 3B). To deter-
mine if GLS2 is critical in affecting radioresistance of cervical cancer, we
generated lentivector expressing GLS2-speciﬁc short hairpin RNA
(shRNA) that could efﬁciently silence the expressions of GLS2 in
transfected HeLaR cells (Fig. 3B). Then, clonogenic survival assay was
performed to measure the radiation response. As shown in Fig. 3C, D,
GLS2 knockdown cells displayed weaker colony formation capacity
compared to other control groups. Intriguingly, the colony formation ca-
pacity of HeLa cells was intermediate between HeLaR cells and GLS2
knockdown cells. We further measured the cellular apoptosis in differ-
ent groups under irradiation. It showed that more apoptotic cells were
detected in GLS2 knockdown group than radioresistant or control
group at 48 h after 6 Gy irradiation (Fig. 3E). The above results indicate
that knocking down the expressions of GLS2 can dramatically increase
the radiosensitivity of HeLaR cells.
3.4. Knocking down GLS2 alters intracellular ROS via decreasing
glutathione, NADH and NADPH levels
Intracellular ROS levels can affect the sensitivity of cells to ionizing
radiation-induced apoptosis.We hypothesized that decreasingGLS2 ex-
pression would lead to elevated levels of intracellular ROS. To addressTable 2
Immunohistochemical analysis of GLS2 expression in radiation-sensitive and radiation-
resistant cervical cancer tissues.
GLS2 staining Total
(n = 144)
p-Value
0 ~ 3 4 ~ 6 7 ~ 9 10 ~ 12
Radiation-sensitive 20 33 21 12 86 0.000257
Radiation-resistant 6 12 27 13 58this hypothesis, the oxidizable ﬂuorogenic probe DHE was used to ex-
amine the redox levels of GLS2 knockdown HeLaR cells, HeLaR cells
andwild type HeLa cells. As shown in Fig. 4B, reduced GLS2 expressions
led to a vast increase in ROS levels in both unstressed and ionizing
radiation-treated cells by ﬂow cytometry. Notably, these GLS2-
negative cells displayed approximately 2.5-fold higher ROS levels com-
pared with HeLaR cells after 6 Gy irradiation (Fig. 4B). Immunoﬂuores-
cence staining was further employed to detect the intracellular ROS
levels. Down-regulation of GLS2 resulted in increased oxidation of
DHE (blue) to 2-OH-E+ (red) when compared to HeLaR and control
cells (Fig. 4A). This data was consistent with the intracellular ROS levels
seen in the quantitative analysis by ﬂow cytometry (Fig. 4B). GLS2 reg-
ulates one of the precursors of GSH, the most important antioxidant
molecule and a scavenger for ROS, and GSH/oxidized glutathione
(GSSG) is the major redox couple that determines the antioxidative ca-
pacity of cells [22]. We measured the GSH levels and GSH/GSSG ratio in
different groups. Our results showed that HeLaR cells displayed higher
levels of GSH and GSH/GSSG ratio compared with other groups, where-
as knocking down of GLS2 expression decreased GSH levels and the
GSH/GSSG ratio in cells (Fig. 4C, D). Given that NADH and NADPH are
also important intracellular antioxidants, we further detected NAD+/
NADH ratio as well as NADH+/NADPH ratio in different groups. Consis-
tent with previous ﬁndings, silencing GLS2 signiﬁcantly decreased
NADH and NADPH levels in cells (Fig. 4E and F). Taken together, these
data indicate that GLS2 regulates intracellular ROS levels through the
GSH, NADH and NADPH-dependent antioxidant systems.
3.5. Knocking down GLS2 expression enhances the radiosensitivity of
cervical cancer xenografts
Mouse xenograft models were established to determine whether
knocking down of GLS2 confers a sensitive phenotype of radioresistant
cervical cancer to radiation in vivo. The groups consisted of the following
(5 mice for each group): wide type HeLa group, radioresistant HeLaR
group, empty vector lentiviruses transfected HeLaR group (control
shRNA) and GLS2-shRNA lentiviruses transfected HeLaR group
(shRNA-GLS2). All animals received 15 Gy of X-ray radiation divided
into 5 fractions when the xenografts in each group reached a mean di-
ameter of 0.6–0.8 cm. At the end of the experiment, the animals were
sacriﬁced and the xenografts were removed. The tumor volumes were
determined and presented as a fold increase or decrease compared to
the tumor size at the primary site (day 12) of each group. By day 25,
the tumor size of HeLaR and control shRNA groups was approximately
4.5-fold greater than that at day 12 respectively, whereas the tumor
size of shRNA-GLS2 group was only about 2-fold greater than the initial
tumor size at day 12 (Fig. 5B). After that, a signiﬁcant delay in tumor
growth was observed. As shown in Fig. 5A and B, the size of the xeno-
grafts in GLS2 knockdown group decreased more dramatically than
those in radioresistant group and other groups. Additionally, xenografts
were weighed when the mice were sacriﬁced at the end of the experi-
ment. As shown in Fig. 5C, the weight of GLS2 knockdown tumors
was dramatically reduced compared to other groups in response to
radiation.
4. Discussion
It is widely known that the ﬁrst reaction in glutaminemetabolism is
hydrolysis of glutamine to glutamate via the amidohydrolase enzyme
glutaminase. Humans express two major isoforms of this enzyme:
GLS1 (kidney-type) and GLS2 (liver-type) from two closely related
genes [23]. It has also been reported that GLS1 and GLS2 seem to have
contrasting effects in tumorigenesis [10]. GLS1 is abundantly expressed
in transformed and rapidly dividing cells. Thus, it has been considered as
“tumor type” because of its function in promoting oncogenic transfor-
mation and proliferation of different types of tumors [24]. While, GLS2
is most likely to be absent in a majority of malignant tumors [25].
Fig. 2. Different radiation-sensitivity of X-ray resistant sub-line HeLaR and the parental HeLa cells. (A) Images of the colonies formed from HeLaR and HeLa cells at 48 h after 6 Gy irradi-
ation. (B) Dose-survival fraction curves of HeLaR and HeLa cells in the presence of different dose of radiation (0–10 Gy). (C, D) Apoptosis assay of HeLaR and HeLa cells at 48 h after 6 Gy
irradiation (*p b 0.05). The error bars are the mean ± SE. (E, F) Cell cycle distribution of HeLaR and HeLa cells at 24 h after 6 Gy irradiation. The results shown are the average of three
independent experiments.
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tissue [12], emerging evidence has revealed that GLS2 expression also
occurs in malignant tumor cells, for example, breast cancer cells [13].
Furthermore, our present ﬁnding demonstrated that GLS2 is also
expressed in cervical cancer. We wondered, to a certain extent, that
GLS2 should be considered as the “tumor type” at least in breast cancer
and cervical cancer. More signiﬁcantly, the major ﬁnding of this study
was that GLS2 is required for maintaining radioresistance of cervical
cancer. To our knowledge, this study is for the ﬁrst to link GLS2 to radio-
sensitivity of cervical cancer cells.
It is interesting to ﬁnd that advance staged human cervical cancer
showed higher levels of GLS2 in radioresistant patient group than radio-
sensitive patient group. One plausible speculation is that GLS2may play
an important role in mediating radioresistance of cervical cancer. To
address this hypothesis, we established a stable radioresistant humancervical cancer cell line and investigated the biochemical pathways in-
volved in GLS2-enhanced cell radioresistance. Our data demonstrate
that the expression of GLS2 is also higher in radioresistant cancer cells
than radiosensitive cells. This ﬁnding is consistent with the clinical ob-
servation that failure of radiotherapy in cervical cancers is usually asso-
ciated with enhanced levels of GLS2. Then, we used shRNA to stably
knock down GLS2 expression in radioresistant cervical cancer cell line.
We found that knocking down GLS2 signiﬁcantly enhanced radiosensi-
tivity of cervical cancer cells in vitro and in vivo. Furthermore, our stud-
ies have shed light on the underlying mechanism through which GLS2
mediating radioresistance of cervical cancer.
Radiotherapy is based on the fact that ionizing radiation destroys
tumor cells. A primary mechanism of ionizing radiation against cancer
cells is the formation of reactive oxygen species (ROS), or free radicals
[26]. When H2O, the most abundant intracellular molecule, is exposed
Fig. 3. The effect of GLS2 knockdown on radiosensitivity of cervical cancer cells in vitro. (A) The protein levels of GLS2 in different cancer cell lines. (B) The protein levels of GLS2 in HeLa
cells, HeLaR cells and HeLaR cells that were stably infected with GLS2-shRNA lentiviruses (shRNA-GLS2) or empty vector lentiviruses (control shRNA). (C) Images of the colonies formed
from HeLa, HeLaR, control shRNA and shRNA-GLS2 cells in the presence of irradiation. (D) Dose-survival fraction curves of HeLa, HeLaR, control shRNA and shRNA-GLS2 cells in the pres-
ence of different dose of radiation (0–10 Gy) respectively. (E) Apoptosis assay of HeLa, HeLaR, control shRNA and shRNA-GLS2 cells at 48 h after 0 Gy and 6 Gy irradiation (*p b 0.05,
**p b 0.01). Data are mean ± SE, n = 3.
3002 L. Xiang et al. / Biochimica et Biophysica Acta 1833 (2013) 2996–3005to ionizing radiation, decomposition reactions occur, which generate a
variety of free radicals such as superoxide anion radical (O2•−), hydrogen
peroxide (H2O2) and hydroxyl radical (•OH). Excessive accumulation of
ROSwithin cells results in oxidative stress that leads to oxidative damage
to critical cellular biomolecules (DNA, protein, and lipids) [27]. In aword,
ROS plays a critical role in cell death caused by ionizing radiation [28].
However, ionizing radiation-induced changes in cellular antioxidant de-
fense system are believed to suppress ROS-induced cytotoxicity [29].
Glutathione (GSH), one of the major antioxidant enzymes is known to
play an important role in cellular defense against radiation [26]. GSH
not only directly scavenges ROS, reactive nitrogen species, and reactive
metabolites but also serves as an important cofactor in enzymatic
redox reactions [30,31]. Several previous studies indicated that chemo-
and radio-resistant tumor cells have increasedGSH levels [32]. Depletion
of GSH caused enhancement of radiosensitivity in different human
tumor cells [33,34]. GLS2 regulates cellular production of glutamate
which is one of the precursors of GSH [10]. We wondered whether
GSH contributes to theGLS2-enhanced radioresistance of cervical cancer.To address this question, we detected the levels of GSH in GLS2 knock-
down cells. Interestingly, GLS2 knockdown decreased GSH levels and
the GSH/GSSG ratio, whereas there is a signiﬁcantly increasing of GSH
levels and the GSH/GSSG ratio in radioresistant tumor cells. Our ﬁndings
are consistentwith results fromother researchers, who also showed that
GLS2 could increase GSH production and decrease ROS levels in cells
[35].
Altering the expression of one antioxidant enzyme may inﬂuence
the expression of other antioxidant enzymes as compensatory mecha-
nisms in order to sustain a reduced redox environment [26]. NADH
and NADPH are also known as important intracellular antioxidants
and reductants. Our results further showed that GLS2 expression regu-
lates intracellular NADH and NADPH production. We found that NADH
and NADPH levels also enhanced in radioresistant tumor cells, whereas
GLS2 knockdown decreased NADH and NADPH levels in resistant cervi-
cal cancer cells. Taken together, we have shown that GLS2 plays an im-
portant role in regulating radiosensitivity of human cervical carcinomas.
Decreasing GLS2 expression in radioresistant cervical cancer cells
Fig. 4. The effect of GLS2 knockdown on changing intracellular ROS levels response to irradiation and controlling intracellular antioxidants. (A) Representative confocal images of intra-
cellular ROS (red) produced byHeLa, HeLaR, control shRNA and shRNA-GLS2 cells in the presence of irradiation. (B) Flow cytometrymeasurement of ﬂuorescence intensity of intracellular
ROS from different groups in the presence of 0 Gy and 6 Gy irradiation respectively. Detection of intracellular GSH levels (C), relative GSH/GSSG ratio (D), relative NAD+/NADH ratio
(E) and relative NADH+/NADPH ratio (F). (mean ± SE; n = 3; *p b 0.05, **p b 0.01, ***p b 0.001).
3003L. Xiang et al. / Biochimica et Biophysica Acta 1833 (2013) 2996–3005increases in vitro and in vivo sensitivity to ionizing radiation. In addition,
our data indicate that downregulation of GLS2 expression decreases cel-
lular antioxidants GSH, NADH and NADPH production and eventually
increases cellular ROS levels, which suggests a possible mechanism for
the observed sensitization.
Regarding to the molecular mechanism which leading to the GLS2
overexpression in cervical cancer, we are thinking that GLS2might be in-
ducedby activation of radiation dependent EGFR/ERK signaling pathway.
As we know cells respond to irradiation damage by triggering theactivation of cell surface receptors, such as epidermal growth factor re-
ceptor (EGFR)[36], resulting in the phosphorylation of extracellular
signal-regulated kinase (ERK), p38 MAPK (p38 kinase), or c-Jun NH2-
terminal kinases (JNK) signaling pathways[37,38]. We found that phos-
phorylation of ERK is increased in HeLaR cells but not MAPK or JNK
(data not shown). Additionally, recent data fromother labs show that ac-
tivated ERK signaling pathway upregulates glutamine metabolism as
well as glutaminase activity [39,40]. Our further work is to conﬁrm
whether EGFR/ERK signaling pathway upregulates GLS2 expression in
Fig. 5. The effect of GLS2 knockdown on radiosensitivity of cervical cancer cells in xeno-
grafts. (A) The ﬁnal tumor volumes in different tumor groups after irradiation treatment.
Animals (n = 5 per group) received 15 Gy of X-radiation divided into 5 fractions on days
14, 18, 22, 26, and 30. (B) The growth curves of xenografts generated by HeLa, HeLaR,
control shRNA and shRNA-GLS2 cells. Data are expressed as the mean change in tumor
volumes relative to the initial tumor volumes on day 12. (C) The statistical histogram of
theﬁnal xenografts weight in different groups of sacriﬁcedmice is also shown (*p b 0.05).
3004 L. Xiang et al. / Biochimica et Biophysica Acta 1833 (2013) 2996–3005radioresistant cervical cancer cells. Furthermore, we speculate that some
transcriptional factors might also contribute to the upregulation of
GLS2, such as hypoxia inducible factor-1 (HIF-1). Hypoxia and HIF-1
are signiﬁcantly associated with cancer resistance to radiotherapy.
There are increased data show that hypoxia regulate the activity levelsof glutamine synthetase, glutaminase as well as glutamate metabolism
[41,42]. We also try to ﬁnd out whether HIF-1 could regulate GLS2
expression in a directly or indirectly way.
Given the role of GLS2 in mediating cervical cancer radioresistance,
GLS2 should be a potential target to improve the efﬁciency of radiosen-
sitivity in cervical cancer. Future investigations should be focus on the
role of some other intracellular antioxidants which may also involve
in GLS2-mediating radioresistance of cervical cancer. Additionally,
precise mechanisms responsible for the GLS2 signaling pathway are
required.
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